Mag 2 2.25 g - powder for oral solution - magnesium deficiency - 20 bags

One sachet contains: magnesium pidolate 2.250 g (corresponding to 184 mg of Mg++ ion).

 

Granules for oral solution: sodium saccharin, citric acid monohydrate, sucrose, lemon flavouring.

 

For adults only: 3 vials or 2 sachets of granules per day. In children, the dosage may be established by a doctor after consultation. Caution: use only for short periods of treatment.

 

In patients with renal insufficiency, it is necessary to reduce the dosage and monitor renal function and magnesium levels. It is advisable to consider the possibility that cardiovascular and respiratory depression may occur during treatment. Each vial contains 3.5 g of sucrose. Each sachet contains 2.985 g of sucrose. If taken according to the recommended dose, the daily intake of sucrose corresponds to 10.5 g for the vials and 5.97 g for the sachets. Patients with rare hereditary problems of fructose intolerance, glucose-galactose malabsorption, or sucrase-isomaltase insufficiency should not take this medicine. The oral solution contains p-hydroxybenzoates: they can cause allergic reactions (possibly delayed) and, exceptionally, bronchospasm.

 

Hypersensitivity to the active substance or to any of the excipients. Severe renal insufficiency (creatinine clearance less than 30 ml/min). Not to be administered to patients undergoing digitalis therapy.

 

Rare digestive disorders, diarrhea, abdominal pain. Exceptional cases of individual intolerance to magnesium have been reported, which can be treated with oral or parenteral antihistamines.

 

Oral magnesium administration may result in reduced absorption of tetracyclines, therefore it is recommended not to administer the drug simultaneously with tetracycline-based drugs, but to maintain at least 3-4 hours between the two administrations. Quinolones should be administered at least 2 hours before or 6 hours after the administration of magnesium-based products to avoid interference with their absorption. In the case of concomitant administration of magnesium-based products and cholecalciferol (vitamin D3), monitoring of calcium levels is recommended to avoid the possible onset of hypercalcemia. The concomitant use of preparations containing calcium or phosphate salts is not recommended as these products prevent the absorption of magnesium. Concomitant use of magnesium-based products with drugs that depress the central nervous system may enhance the effects of magnesium on the CNS and must be carefully evaluated.

 

It is advisable to take the drug during pregnancy and breastfeeding under medical supervision and only in cases of actual need. Magnesium is considered compatible with breastfeeding.

 

Granules for oral solution: no storage precautions.

 

Pack with 20 sachets.